|
| Primary information |
|---|
| ID | 15037 |
| Therapeutic ID | Th1564 |
| Protein Name | Bezlotoxumab |
| Sequence | >Th1564_Bezlotoxumab
EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | 19 Days |
| Description | Bezlotoxumab is a human monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. Used to reduce the recurrence of Clostridium difficle infection in adults receiving antibiotic therapy to treat C. difficile infection and high risk of recurrence. |
| Indication/Disease | Prevents recurrence of Clostridium difficile infection in people 18 years or older who are either currently receiving treatment for C. difficile infection or have a high risk of recurrence. |
| Pharmacodynamics | Bezlotoxumab binds to C.difficile toxin B, a virulence factor common to practically all C.difficile, which prevents the bacteria from infecting host cells. Bezlotoxumab binds two epitopes of toxin B, via two Fab regions, which partially blocks the carbohydrate binding pockets of the toxin resulting in the prevention of toxin B from binding to host cells. |
| Mechanism of Action | A single molecule of bezlotoxumab neutralizes Toxin B by binding its two Fab regions to two epitopes within the N-terminal half of the Toxin B CROP domain, partially blocking the carbohydrate binding pockets of the toxin and preventing toxin binding to host cells. |
| Toxicity | No data available on overdosage. |
| Metabolism | Catabolism |
| Absorption | Not absorbed since give IV |
| 7.33L |
| Clearance | 0.317 L/day |
| Categories | Amino Acids, Peptides, and Proteins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Clostridium difficile Toxin B |
| Brand Name | Zinplava |
| Company | Merck Sharp & Dohme Corp. |
| Brand Description | Merck Sharp & Dohme Corp. |
| Prescribed For | Intravenous |
| Chemical Name | 25 mg/1mL |
| Formulation | None. |
| Physical Appearance | nausea, fever, and headache. |
| Route of Administration | Zinplava is a monoclonal antibody. Monoclonal antibodies are made to target only certain cells in the body. Bezlotoxumab works by binding to a specific toxin produced by the Clostridium difficile bacteria, to help neutralize the toxin's effects. Zinplava is used together with antibiotic medicine in adults... |
| Recommended Dosage | Zinplava is a prescription medicine used to treat the symptoms of Clostridium difficile infection (CDI). Zinplava may be used alone or with other medications. |
| Contraindication | NA |
| Side Effects | Bezlotoxumab is a human monoclonal antibody that binds to C. difficile toxin B and neutralizes its effects. Bezlotoxumab is an IgG1 immunoglobulin with an approximate molecular weight of 148.2 kDa. |
| Useful Link 1 | Link |
| Useful Link 2 | Link |
| Remarks | NA |